|
466
|
| 2119 |
TOR signaling
|
|
decreases_activity of
|
EIF4EBP1
|
|
| 2121 |
TOR signaling
|
|
increases_phosphorylation of
|
EIF4EBP1
|
|
| 2122 |
Rapamycin
|
|
decreases_activity of
|
TOR signaling
|
|
| 4049 |
PINK1-mut
|
|
decreases_activity of
|
TOR signaling
|
|
| 4050 |
PARK2-mut
|
|
decreases_activity of
|
TOR signaling
|
|
|
19684592
|
Parkinson disease
|
|
736
|
| 4321 |
TOR signaling
|
|
increases_phosphorylation of
|
LPIN1
|
at Ser106 of LPIN1; if insulin-stimulated
|
|
18023282
|
Diabetes mellitus, type II
Obesity
Lipodystrophy
Insulin resistance
Fatty liver disease, nonalcoholic
Majeed syndrome
|
|
1,429
|
| 9997 |
RAB1A
|
NOT |
affects_activity of
|
TOR signaling
|
|
| 9998 |
SNCA
|
NOT |
affects_activity of
|
TOR signaling
|
|
|
20855506
|
Parkinson disease
|
|
1,513
|
| 10727 |
Resveratrol
|
|
decreases_activity of
|
TOR signaling
|
in mice on high-calorie diet
|
|
17086191
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,822
|
| 13669 |
DDIT4
|
|
decreases_activity of
|
TOR signaling
|
|
|
21258409
|
Neurological
|
|
2,814
|
| 37684 |
phosphatidylinositol 3-kinase signaling
|
|
increases_activity of
|
TOR signaling
|
|
|
21912508
|
Diabetes mellitus, type II
Cancer
Insulin resistance
Metabolic syndrome
|
|
2,842
|
| 26202 |
Metformin
|
|
affects_activity of
|
TOR signaling
|
|
|
21655990
|
Breast cancer
Diabetes mellitus, type II
Insulin resistance
|
|
2,848
|
| 26252 |
Metformin
|
|
decreases_activity of
|
TOR signaling
|
|
|
19822355
|
Diabetes mellitus, type II
Cancer
Insulin resistance
|
|
3,513
|
| 32787 |
increased circulating branched-chain amino acid level
|
|
increases_activity of
|
TOR signaling
|
|
| 32788 |
TOR signaling
|
|
increases_activity of
|
Insulin resistance
|
|
|
19356713
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
3,527
|
| 32809 |
Ketamine
|
|
increases_activity of
|
TOR signaling
|
|
|
20724638
|
Major depressive disorder
|
|
3,532
|
| 32871 |
toll-like receptor signaling pathway
|
|
increases_activity of
|
TOR signaling
|
via phosphoinositide 3-kinase/Akt1
|
| 32977 |
AKT1
|
|
increases_activity of
|
TOR signaling
|
via phosphoinositide 3-kinase/Akt1
|
|
18924132
|
Immunological
|
|
3,656
|
| 34820 |
Amino acid
|
|
affects_activity of
|
TOR signaling
|
|
|
17956307
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,795
|
| 37704 |
Leucine
|
|
increases_activity of
|
TOR signaling
|
in hypothalamus
|
| 37705 |
TOR signaling
|
|
increases_activity of
|
decreased food intake
|
|
| 37707 |
Valine
|
NOT |
increases_activity of
|
TOR signaling
|
in hypothalamus
|
|
18765678
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,799
|
| 37785 |
leucine deprivation
|
|
decreases_activity of
|
TOR signaling
|
|
|
21282364
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,801
|
| 37781 |
leucine deprivation
|
|
decreases_activity of
|
TOR signaling
|
|
| 37788 |
EIF2AK4
|
|
decreases_activity of
|
TOR signaling
|
under leucine deprivation
|
|
21282364
|
Diabetes mellitus, type II
Insulin resistance
|
|
4,096
|
| 42380 |
TOR signaling
|
|
affects_expression of
|
EPAS1
|
in POMC neurons, in hypothalamus
|
|
21814490
|
Diabetes mellitus, type II
Insulin resistance
|
|
4,802
|
| 47499 |
Amino acid
|
|
increases_activity of
|
TOR signaling
|
in liver
|
| 47503 |
Glucagon
|
|
decreases_activity of
|
TOR signaling
|
in liver
|
|
15494402
|
Diabetes mellitus, type II
Insulin resistance
|
|
4,993
|
| 49303 |
Rapamycin
|
|
decreases_activity of
|
TOR signaling
|
|
| 49307 |
TOR signaling
|
|
increases_expression of
|
SCARB1
|
|
|
24713582
|
Cardiovascular disease
|
|
5,873
|
| 55534 |
cilium
|
|
affects_activity of
|
TOR signaling
|
|
|
20972424
|
Diabetes mellitus, type II
Insulin resistance
|
|
5,876
|
| 55585 |
AMPK
|
|
decreases_activity of
|
TOR signaling
|
in pancreatic beta cells
|
| 55586 |
TOR signaling
|
|
affects_activity of
|
negative regulation of cell size
|
in pancreatic beta cells
|
|
19808022
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,191
|
| 57837 |
Vorinostat
|
|
decreases_activity of
|
TOR signaling
|
|
|
23147569
|
Cancer
|
|
6,193
|
| 57853 |
Metformin
|
|
decreases_activity of
|
TOR signaling
|
in glioblastoma cells
|
|
25867026
|
Diabetes mellitus, type II
Glioblastoma
Insulin resistance
|
|
6,195
|
| 57961 |
TOR signaling
|
|
affects_activity of
|
Glioblastoma
|
|
| 57990 |
TOR signaling
|
|
decreases_activity of
|
TP53
|
|
| 57991 |
TP53
|
|
decreases_activity of
|
TOR signaling
|
|
| 58000 |
Glioblastoma
|
|
increases_activity of
|
TOR signaling
|
|
|
23625692
|
Glioblastoma
|
|
6,206
|
| 58408 |
Valproic acid
|
|
decreases_activity of
|
TOR signaling
|
|
| 58414 |
TOR signaling
|
|
affects_activity of
|
MYC
|
|
|
23866964
|
Burkitt lymphoma
Cancer
|
|
6,209
|
| 58755 |
single-bout exercise
|
|
increases_activity of
|
TOR signaling
|
until AMPK signaling had subsided.
|
|
23802289
|
Metabolic
|
|
6,210
|
| 58786 |
RPS6-phos
|
|
affects_activity of
|
TOR signaling
|
|
| 58787 |
Vorinostat
|
|
decreases_activity of
|
TOR signaling
|
in ESS-1 cells;
|
|
18850582
|
Metabolic
Endometrial cancer
|
|
6,258
|
| 58582 |
SMAD1
|
|
increases_activity of
|
TOR signaling
|
|
| 58583 |
SMAD5
|
|
increases_activity of
|
TOR signaling
|
|
| 58584 |
TOR signaling
|
|
increases_activity of
|
skeletal muscle hypertrophy
|
|
| 58586 |
MTOR
|
|
increases_activity of
|
TOR signaling
|
|
| 58593 |
SMAD6
|
|
decreases_activity of
|
TOR signaling
|
via the suppression of BMP-regulated Smads.
|
|
24145169
|
Metabolic
Muscular
|
|
6,262
|
| 58637 |
Entinostat
|
|
decreases_activity of
|
TOR signaling
|
in leukemia cells
|
| 58642 |
Everolimus
|
|
decreases_activity of
|
TOR signaling
|
in leukemia cells
|
|
18784743
|
Leukemia, acute myeloid
|
|
6,273
|
| 58814 |
Rapamycin
|
|
decreases_activity of
|
TOR signaling
|
in MDA-MB-231 breast cancer cells, in U251 glioma cells; via the mTORC1 complex
|
|
23730416
|
Breast cancer
Glioblastoma
|
|
6,301
|
| 60116 |
TOR signaling
|
|
affects_activity of
|
T-cell lymphopoiesis
|
|
|
25674239
|
Cancer
Cutaneous T-cell lymphoma
Peripheral T-cell leukemia / lymphoma
Angioimmunoblastic T-Cell lymphoma
|
CIDeR